Cargando…

Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), significantly reduces mortality and morbidity in patients with chronic heart failure with a reduced ejection fraction (HFrEF). However, a considerable number of patients treated with sacubitril/valsartan experience hypotensio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Moo Jun, Jang, Ha Nee, Song, Haa-Na, Lee, Jong Sil, Kang, Min Gyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177371/ https://www.ncbi.nlm.nih.gov/pubmed/34707049 http://dx.doi.org/10.2169/internalmedicine.8373-21

Ejemplares similares

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
por: Li, Kangbo, et al.
Publicado: (2023)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
por: Li, Wanjing, et al.
Publicado: (2022)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
por: Cho, In-Jeong, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
por: Habibi, Javad, et al.
Publicado: (2019)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
por: Sun, Yuxi, et al.
Publicado: (2021)

Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis
por: Wang, Yiwen, et al.
Publicado: (2019)

Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect
por: Kim, Heungjo, et al.
Publicado: (2022)

Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation
por: Zhu, Tianyu, et al.
Publicado: (2022)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
por: Kashiwagi, Yusuke, et al.
Publicado: (2023)

Acute asymptomatic hyponatraemia following inpatient initiation of angiotensin receptor–neprilysin inhibitor: a case report
por: Dean, John-Henry L, et al.
Publicado: (2023)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Long‐term impact of angiotensin receptor‐neprilysin inhibitor based on short‐term treatment response in heart failure
por: Park, Hyuk Kyoon, et al.
Publicado: (2023)

The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis
por: Kotak, Sohny, et al.
Publicado: (2023)

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
por: Hsu, Shao-Jung, et al.
Publicado: (2020)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
por: Choi, Hong-Mi, et al.
Publicado: (2020)

Angiotensin receptor‐neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime
por: Arcudi, Alessandra, et al.
Publicado: (2022)

Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation
por: Dong, Youzheng, et al.
Publicado: (2023)

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
por: Kato, Tomoko, et al.
Publicado: (2023)

Management of pulmonary hypertension associated with valvular heart disease with angiotensin‐receptor neprilysin inhibitor
por: Ali, Hyeon‐Ju Ryoo, et al.
Publicado: (2023)

Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure
por: Ding, Kun, et al.
Publicado: (2022)

The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022
por: Xu, Xia, et al.
Publicado: (2022)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19
por: Bellis, Alessandro, et al.
Publicado: (2020)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
por: Taghavi, Sepideh, et al.
Publicado: (2020)

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
por: Gan, Liangying, et al.
Publicado: (2022)

Effects of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) on the Glucose and Fat Metabolism Biomarkers Leptin and Fructosamine
por: Ohnewein, Bernhard, et al.
Publicado: (2023)

Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy
por: Kim, In-Cheol, et al.
Publicado: (2022)

Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials
por: Bratsos, Sosipatros
Publicado: (2019)

Angiotensin Receptor‐Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
por: Sharifi Kia, Danial, et al.
Publicado: (2020)

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
por: Tsai, Ming-Lung, et al.
Publicado: (2023)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a4o7h9o9cpn7q8mkc1fim4pd74